Sandoz Group (OTCMKTS:SDZNY) Stock Rating Upgraded by Erste Group Bank

Sandoz Group (OTCMKTS:SDZNY) was upgraded by stock analysts at Erste Group Bank to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Separately, Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Four analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Sandoz Group currently has a consensus rating of “Strong Buy”.

Sandoz Group Stock Performance

OTCMKTS SDZNY opened at $85.14 on Thursday. The company has a current ratio of 1.18, a quick ratio of 0.77 and a debt-to-equity ratio of 0.53. The firm’s 50 day simple moving average is $85.86 and its 200 day simple moving average is $83.75. Sandoz Group has a 1 year low of $55.42 and a 1 year high of $94.15.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.